Datapoint: Libtayo Scores NSCLC Nod, Will Take On Keytruda

Sanofi and Regeneron’s Libtayo last week scored its third FDA approval, this time for first-line treatment of advanced non-small cell lung cancer (NSCLC) in patients whose tumors have high PD-L1 expression. The drug will now have to face off against Merck’s Keytruda, a behemoth in the competitive lung cancer market basket. For the treatment of NSCLC, Keytruda currently holds preferred formulary placement for 6% of all covered lives, growing to 17% with utilization management restrictions applied.

SOURCE: MMIT Analytics, as of 2/24/21

0 Comments

AIS Health Staff

Related Posts

https://www.mmitnetwork.com/wp-content/uploads/2021/08/post-default-img.jpg
October 18

Datapoint: AmeriHealth Caritas to Enter Exchange Market

Read More
https://www.mmitnetwork.com/wp-content/uploads/2021/09/wordpress-featured-image-datapoints.jpg
October 14

Datapoint: Ochsner to Launch MA Org in Louisiana

Read More
https://www.mmitnetwork.com/wp-content/uploads/2021/09/wordpress-featured-image-datapoints.jpg
October 13

Datapoint: Three States to Launch New Exchange Marketplaces

Read More

GAIN THERAPEUTIC AREA-SPECIFIC INTEL TO DRIVE ACCESS FOR YOUR BRAND

Sign up for publications to get unmatched business intelligence delivered to your inbox.

subscribe today